×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Volver a Agenda
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Session Chair(s)
William Gregory, PhD
Senior Director, Safety and Risk Management
Pfizer Inc, United States
Session 4: Special Safety Considerations in Benefit-Risk Equipoise of Allogeneic Chimeric Antigen Receptor T (alloCAR-T) Cell Therapies
Speaker(s)
Speaker
Peter F. Bross, MD
FDA, United States
Medical Review Officer OTAT, CBER
Speaker
William Gregory, PhD
Pfizer Inc, United States
Senior Director, Safety and Risk Management
¿Tiene una cuenta?